The DPP4 inhibitor, such as linagliptin and alogliptin, can dramatically mitigate AGE and AGE receptor axis activity, thus alleviating the renal damage caused by inflammation, proteinuria, and oxidative stress in type 1 diabetes (T1DM) and T2DM (54, 55). Here, DPP4 is linked to type 1 diabetes mellitus.